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Platelets have been long postulated to play a critical role in the pathogenesis of prostate cancer, although relatively
little is known regarding the precise mechanisms involved. Androgen deprivation therapy (ADT) for prostate cancer
eventually fails with relapse occurring in the form of castration-resistant prostate cancer (CRPC). CRPC tumors
typically overexpress androgen receptor (AR), demonstrating continued dependence upon AR signaling. Platelets
have been previously demonstrated to contain androgens, and we sought to explore the contribution of platelet-
derived androgens in CRPC. In this study, we examined the role of platelet-derived androgens in vitro using
platelets from men with CRPC, men with high-risk prostate cancer, and healthy male donors. A series of in vitro
assays was performed to elucidate the impact of platelet-derived androgens on androgen-sensitive prostate tumor
cells. By examining platelet-derived androgen effects on AR signaling in prostate tumor cells, we found that
platelets, from men with CRPC and on ADT, strongly induce AR target genes and tumor cell proliferation.
Moreover, we show a fully intact testosterone (T) biosynthetic pathway within platelets from its precursor
cholesterol and demonstrate that platelets of CRPC patients with ADT resistance are able to generate T. Overall,
our findings reveal an unknown capacity of platelets to synthesize T at functionally relevant levels in patients with
lethal prostate cancer. Importantly, it suggests a novel paracrine mechanism of T production that may act to
sustain CRPC state and potentiate therapeutic resistance.
Neoplasia (2015) 17, 490–496Creativity Award. A.S. and G.S.P. received support from NCI/NIH - UCA167234A
and from the Department of Defense - W81XWH-12-1-0130. Some experimental data
were obtained by the metabolomics Core Services supported by grant U24 DK097153
of National Institutes of Health Common Funds Project to the University of Michigan.
Received 6 May 2015; Accepted 19 May 2015
© 2015 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open accessarticle under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1476-5586
http://dx.doi.org/10.1016/j.neo.2015.05.003
Neoplasia Vol. 17, No. 6, 2015 Platelet-Synthesized Testosterone in Men with PC Zaslavsky et al. 491Introduction
The androgen receptor (AR)–mediated cellular program is a driving force
in the process of prostate carcinogenesis [1]. For men with advanced
disease, initial therapy consists of androgen-ablative strategies. Unfortu-
nately, despite an initial response, most tumors relapse in the form of
castration-resistant prostate cancer (CRPC), a lethal condition that
accounts for approximately 30,000 deaths in the United States annually
[2]. Notably, despite systemic androgen ablation, CRPC tumors exhibit
continued cellular dependence on AR signaling. A variety of mechanisms
have been demonstrated to support the castrate-resistant state including
amplification and mutations of the AR gene, ligand-independent
activation of AR, and dysregulation of AR gene coactivators and
repressors, among others [3,4]. In addition, intratumoral prostate cancer
cell production of androgens has also been shown to play an important
role in the sustenance of CRPC tumors [5,6]. It is important to note that
the current generation of androgen-ablative therapies (e.g., abiraterone)
seeks to block this source of androgen synthesis [7].
Platelets have been postulated to perform a critical function in the
pathogenesis of prostate cancer for decades [8,9], yet the precise nature of
this interaction remains poorly understood. Proposed ways platelets may
induce prostate cancer progression include the local delivery of growth
factors and the protection of circulating tumor cells from immune
surveillance [10–12]. Intriguingly, platelets have also been shown to
produce the androgen dehydroepiandrosterone [13], raising the possibility
of an additional mechanism through which platelets might support
prostate cancer growth. This observation motivated us to assess
intraplatelet testosterone (T) levels in men with advanced prostate cancer;
interrogate the capacity of platelets to produce T from its precursor
cholesterol, specifically in the castrate-resistant state; and test the ability of
platelet-derived T to induce androgen signaling within prostate cancer
cells. The findings presented in this work provide novel insight into a
previously unknown role for platelets in the pathogenesis of prostate cancer
and importantly identify platelets as both potentially new therapeutic
targets as well as markers of extragonadal androgen biosynthesis.
Material and Methods
Reagents
All metabolites were from Sigma-Aldrich (St. Louis, MO): 13C-T (cat
no. 73610), 13C-cholesterol (cat no. 749478), and 13C-pregnenolone
(cat no. 740985). Bicalutamide was a kind gift of Dr. Chinnaiyan
(University of Michigan). Abiraterone acetate (cat no. SC-207240) was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Culture
Human prostate cancer cell lines LNCaP and PC3 were obtained
from the American Type Culture Collection (Manassas, VA), and
LNCaP-AR cells were a kind gift from Dr. C. Sawyers (Memorial
Sloan Kettering Cancer Center, New York, NY). All cells were
authenticated by the University of Michigan DNA Sequencing Core
using short tandem repeat DNA fingerprinting. Cells were
maintained in the RPMI 1640 medium (Gibco; Life Technologies)
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine,
100 U/ml penicillin G sodium, and 100 μg/ml streptomycin sulfate.
Platelet Isolation
Written informed consent in accordance with the Declaration of
Helsinki was received from all participants before inclusion in the
study. All patient samples were obtained under an institutional review
board–approved protocol at the University of Michigan followinginformed consent. Human platelets were isolated from venous blood
from healthy subjects or prostate cancer patients not taking
antiplatelet drugs (e.g., aspirin, long-term nonsteroidal anti-inflam-
matory drugs, clopidogrel). Separation of platelets from whole blood
was achieved by centrifugation (1000 rpm for 20 minutes at room
temperature). Platelet-rich plasma was then transferred into a separate
tube, and prostaglandin-1 (500 ng/ml) was added to prevent platelet
activation. Platelets were then precipitated by centrifugation at room
temperature for 5 minutes at 2200 rpm and washed extensively in
wash buffer (140 mM NaCl, 5 mM KCl, 12 mM trisodium citrate,
10 mM glucose, 12.5 mM sucrose, pH 6.0). Harvested platelets were
then counted with a Coulter counter (Beckman Coulter, Fullerton,
CA) and resuspended in platelet buffer (PB) (10 mM N-2-hydrox-
yethylpiperazine-N’-2-ethanesulfonic acid, 140 mM NaCl, 3 mM
KCl, 0.5 mM MgCl2, 5 mM NaHCO3, 10 mM glucose) before use.
Cell Proliferation
Cells were seeded into Poly-L-Lysine (Sigma-Aldrich)–coated
12-well plates at a density of 5 × 103 cells per well in RPMI 1640
containing 10% FBS. Medium was replaced 18 hours later with
platelet buffer alone (control) or with human platelets (10 × 106/ml)
resuspended in platelet buffer (treatment). Cell counts were done
using a Coulter counter (Beckman Coulter) at indicated time points
in triplicates. At least three independent experiments were performed.
Quatitative reverse transcriptase polymerase chain reaction
Cells were seeded into six-well plates (CellBIND) from Corning
(Corning, NY) at a density of 5 × 105 cells per well in RPMI 1640
containing 10% FBS. Approximately 18 hours later, attached cells were
androgen deprived for the next 48 hours by replacing the media with
phenol red–free RPMI supplemented with 1% charcoal-stripped serum
(CSS) from Life Technologies (Grand Island, NY). CSS containing
media was replaced every 12 hours for the next 48 hours. For
bicalutamide experiments, drug (10 μM) was added for 10 hours in
10%CSS phenol red–free RPMI and then added again in platelet buffer
immediately before platelet addition. Either platelet buffer alone or
platelets (150,000/μl) in 3 ml of platelet buffer were added to the cells.
After 24-hour incubation with platelets in a cell incubator, cells
were washed 2× with phosphate-buffered saline (PBS) and lysed in
Trizol (Life Technologies). RNA extraction from Trizol was
performed according to the manufacturer’s protocol; BioRad iScript
cDNA synthesis kit was used for reverse transcriptase polymerase
chain reaction (PCR) (BioRad, Hercules, CA). Quantitative PCR was
performed using BioRAD SYBR Green Mastermix on an Applied
Biosystems 7300 Real-Time PCR system. All reactions were
performed in triplicates. Fold mRNA expression was calculated
using 2−ΔΔCT method [14]. Primers were synthesized by Integrated
DNA Technologies (Coralville, IA). Primers used were as follows:
PSA: (forward) 5’-TGACCAAGTTCATGCTGTGT-3’ and (reverse)
5’-GTCATTTCCAAGGTTCCAAG-3’; TMPRSS2: (forward) 5’-
CAGGAGTGTACGGGAATGTGATGGT-3’ and (reverse) 5’-GAT
TAGCCGTCTGCCCTCATTTGT-3’; GAPDH: (forward) 5’-GCA
CCGTCAAGGCTGAGAAC-3’ and (reverse) 5’-TGGTGAAGACG
CCAGTGGA-3’.
Immunoblot
Platelet protein extracts were prepared using cell lysis buffer
(Cell Signaling; cat no. 9803S) with protease inhibitors (Thermo
Scientific; cat no. 78410). Protein concentrations were determined by
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(BioRAD) with β-ME and analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis. One hundred micrograms of
protein was loaded per lane. Proteins were transferred to a nitrocellulose
membrane, blocked in 5% nonfat milk (wt/vol in PBS), and
immunoblotted with indicated primary antibodies and appropriate
horseradish peroxidase–conjugated secondary antibodies. Immunoblots
were developed using Western Lighting Chemiluminescence Reagent
(Milipore, Billerica, MA).
Antibodies anti-CYP17A1 (cat no. SAB1300941), anti-HSD3B2
(cat no. SAB2101087), and anti–actin-HRP (cat no. A3854) were
from Sigma-Aldrich; anti-CYP11A1 (cat no. 12491) was from Cell
Signaling Technology (Danvers, MA).
Mass Spectrometry
Platelets from healthy donors or prostate cancer patients were
isolated from venous blood as described above. For platelet transfer
of T to tumor cells, LNCaP cells were plated on the Poly-L-Lysine
(Sigma-Aldrich)–coated 10-cm dishes in 10% FBS RPMI. The next
day, the medium was replaced with 10% CSS phenol-free RPMI for
the next 24 hours. Washed platelets (~6 × 106) were resuspended in
6 ml of platelet buffer and incubated with 10 μl of 13C-T (1 mg/ml
in ethanol) for 24 hours. After incubation, platelets were washed
2× with wash buffer and then added to the cells in 10-cm dishes.
After 24-hour incubation, control (untreated cells) and platelet-
treated cells were washed with PBS 2×; cells were then fixed by
the addition of ~5 ml of liquid nitrogen. Frozen dishes were
then stored at −80°C before being transferred for mass spectrometry
(MS) analysis.
For metabolite conversion studies, washed platelets (~8 × 104)
were resuspended in 320 μl of platelet buffer. Equal volume of
platelets was then transferred into separate tubes for control
(untreated) and the experiment. One microliter of 13C-cholesterol
(2 mg/Ml in ethanol) and 1 μl of 13C-pregnenolone (1 mg/Ml in
ETHANOL) were then added to the platelet suspension.
To establish the intraplatelet T and dihydrotestosterone (DHT)
concentrations, platelets from patients (5.2 × 106 - 39 × 106 platelets)
were resuspended in 200 μl of platelet buffer. Platelets were then
activated with thrombin (1 U/μl) and centrifuged at 14,000 rpm for
1 minute. Androgen-containing supernatant was then transferred into
a fresh tube and frozen at −80°C before being transferred for MS
analysis. The lower limit of quantification for each androgen using the
MS assay was 10 pg/ml using 100 μl of serum. The intraassay
coefficients of variation for T and DHT were b5%.
For the abiraterone studies, platelets were pretreated with 10 μg
of the drug for 8 hours before either 13C-cholesterol or
13C-pregenenolone was added. After 24-hour incubation at room
temperature, platelets were briefly mixed and thrombin (1 U/μl)
(Sigma-Aldrich) was added to activate platelets. Samples were then
stored at −80°C until ready for MS analyses. The metabolite extraction
method used for platelets and cells was performed as previously
described [15–17]. Estrone was used as an internal standard.
Statistics
For the immunoassay experiment, a two-tailed unpaired t test was
used to compare the T values of controls versus patients; for all other
experiments, two-tailed paired t test was used to compare the samples.
P values less than .05 were considered significant (*); and P values less
than .001, very significant (***).Results
Platelet De Novo Synthesis of Testosterone
We first assessed whether platelets can synthesize T de novo. In
these studies, we co-incubated platelets from healthy donors with the
T lipid precursors cholesterol and pregnenolone labeled with
carbon-13 (13C). We then measured levels of 13C-T in platelets
after 24 hours using MS. We found that platelets were able to
successfully convert both cholesterol and pregnenolone into T as
demonstrated in Figure 1A and DHT (Supplementary Figure S1A).
To further characterize the androgen biosynthetic pathway within
platelets, we interrogated the intraplatelet expression of the T
synthetic enzymes CYP11A1, HSD3B2, and CYP17A1 at the protein
level. Western blot analyses of six healthy donor and six prostate
cancer patient platelet lysates (Table 1) revealed the expression of all
three enzymes required for de novo generation of T within platelets
(Figure 1B). Interestingly, platelets of three CRPC patients (#1, #4,
and #5; Table 1) currently undergoing androgen deprivation therapy
(ADT) and platelets from two patients with high-risk disease showed
elevated levels of CYP17A1 protein as compared with platelets of
healthy controls.
To test whether the T biosynthetic pathway in platelets is accessible
to agents like abiraterone, a CYP17A1-blocking drug (half-life ~15
hours) commonly used in ADT in CRPC patients, we pretreated
platelets from healthy donors with abiraterone before adding
13C-cholesterol. We then measured the ability of platelets to convert
cholesterol into T and DHT by MS analyses and observed that
abiraterone significantly inhibited platelet production of T and DHT,
indicating that platelet T converting enzymes are accessible to
CYP17A1 inhibitors (Figure 1C and Supplementary Figure S1B).
Next, we assessed the capacity of platelets from men with CRPC and
known clinical abiraterone resistance to convert cholesterol into T. We
found that platelets from three of three men with CRPC and known
abiraterone resistance (and undergoing abiraterone treatment at the time
of platelet collection) were able to generate 13C-T (Figure 1D and
Supplementary Figure S1C), signifying that platelets from these men are
able to metabolize cholesterol into T despite systemic CYP17A1
blockade. Interestingly, MS analyses of platelets from a CRPC patient
with abiraterone-sensitive disease on abiraterone treatment at the time of
platelet collection revealed that his platelets were unable to convert
13C-cholesterol into 13C-T (Supplementary Figure S1C).
Platelet-Derived Androgens Stimulate AR Signaling and
Promote Tumor Cell Proliferation
To gain a better understanding of the landscape of intraplatelet
androgen levels, we measured the levels of T and DHT in platelets
from men with prostate cancer using MS analysis. We found
detectable levels of both androgens in platelets of all men studied
(Figures 2A and S2A), and no significant difference between the
intraplatelet levels of T and DHT in men with CRPC (n = 10) or in
men with high-risk (n = 8) disease was observed.
Given the known ability of platelets to interact and deliver content
directly to tumor cells [11,12], we sought to investigate platelet capacity to
deliver T to prostate cancer cells. We first co-incubated platelets with
13C-labeled T and then incubated these loaded platelets with
the androgen-dependent prostate cancer cell line LNCaP under
androgen-deprived cell culture conditions. MS cellular analysis revealed
prostate cancer cell uptake of platelet-derived 13C-T after a 24-hour
incubation period (Figure 2B) indicating that platelet-derived T can be
delivered by platelets and is able to enter prostate cancer cells.
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Figure 1. Platelet de novo synthesis of T. (A) Ratio of 13C-T to an internal standard (isotopically labeled estrone) in healthy donor platelets
(n= 4) preincubated with cholesterol or pregnenolone. “Platelets”: untreated platelets; “Platelets + 13C-Cholesterol”: platelets incubated
with 13C-cholesterol; “Platelets + 13C-Pregnenolone”: platelets incubated with 13C-pregnenolone. Significance: ***P b .001. (B) Western
blot of platelet lysates demonstrating the presence of T biosynthetic enzymes (black arrows) in washed platelets of “patients” (men with
prostate cancer) (from Table 1) and “controls” (healthy donors). Actin was used as loading control. (C) Ratio of 13C-T to an internal
standard in healthy donor platelets (n = 4) preincubated with 13C-pregnenolone and abiraterone acetate at 10 μg/ml. “Platelets”:
untreated platelets; “Platelets + 13C-Pregnenolone”: platelets incubated with 13C-pregnenolone. (D) Graph representing the ratio of 13C-T
to an internal standard in platelets from abiraterone-resistant men with CRPC (n = 3). “Platelets”: untreated platelets; “Platelets +
13C-Cholesterol”: incubated with 13C-cholesterol. Significance: *P b .05. (E) Platelets from a man currently receiving abiraterone
(castration-sensitive disease). “Platelets”: untreated platelets; “Platelets + 13C-Cholesterol”: incubated with 13C-cholesterol.
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following ADT failure include, but are not limited to, AR gene
amplification and overexpression. In this condition, even low levels of
androgens are capable of inducing the AR-associated cellular program
[3,4]. Thus, we treated androgen-dependent LNCaP cells with healthy
donor platelets for 6, 12, and 24 hours under serum- and
androgen-deprived cell culture conditions. We found that pooled
platelets fromhealthymale donors induce activation of the AR-dependent
gene TMPRSS2 (a prostate-specific, androgen-responsive, transmem-
brane serine protease gene) in a time-dependent manner (Figure 2C).Table 1. Prostate Cancer Patients’ Data
Patient
ID
Age Cancer
Type
PSA Gleason
Sum
Therapy Abiraterone
Resistance
Platelet [T]
Levels (pg/ml)
Platelet [DHT]
Levels (pg/ml)
#1 60 CRPC 28.4 – ADT Yes 20.5 27.7
#2 79 HR 20.2 N.A. Radiation – 46.1 76.8
#3 65 HR 7.9 9 Surgery – 13 18.6
#4 76 CRPC 8.1 – ADT Yes 12.3 15.3
#5 80 CRPC 6.1 – ADT Yes 9.2 11.8
#6 67 HR 18 9 Surgery – 49 81.7
Cancer type: CRPC, castration-resistant prostate cancer; HR, high-risk prostate cancer defined as
Gleason sum N8 and/or PSA N20 ng/ml. “PSA”: PSA levels at the time platelets were collected.
Gleason sum at the time of platelet collection or not available (N.A.). “Therapy”: type of treatment
at the time of platelet collection. “Platelet [T] levels”: concentration of T pg/ml in 1 × 106 platelets.
“Platelet [DHT] levels”: concentration of dehydrotestosterone pg/ml in 1 × 106 platelets. Patients
#1, #4, and #5 have abiraterone resistance as indicated by their rising PSA levels (not shown).BecauseTMPRSS2 has been also implicated in cell proliferation, we then
examined the effect of platelets on prostate cancer cell proliferation and
observed that, in serum- and androgen-deprived cell culture conditions,
platelets induced cell proliferation of androgen-responsive LNCaP cells
(Supplementary Figure S2B) but had no effect on the AR-negative
prostate cancer cell line PC3 (Supplementary Figure S2C), suggesting
that, under these conditions, platelet influence on prostate cancer cells
may be mediated via androgens rather than the delivery of other
platelet-derived growth factors.
We confirmed our proliferation studies using platelets from men
with prostate cancer (Table 1) and LNCaP cells genetically
engineered to overexpress AR (LNCaP-AR). After 72 hours of
platelet incubation under serum- and androgen-deprived conditions,
we observed a significant induction of proliferation of LNCaP-AR
cells by platelets from men with prostate cancer (Figure 2D). These
studies indicate that platelet-derived androgens are capable of
stimulating CRPC-like (i.e., AR overexpressing) cells.
Platelet-Derived Testosterone Induces AR Target Genes in
CRPC-Like Cells
To assess the ability of platelet androgens to drive AR signaling in
prostate cancer cells, we treated CRPC-like LNCaP-AR cells with
platelets in the presence of the AR antagonist bicalutamide. Under
these conditions, healthy donor platelets were unable to activate AR,
indicating that platelet induction of both prostate-specific antigen
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functional AR (Figure 3A, left and right panels).
To further investigate the impact of platelet androgens on AR gene
transcription, we assessed the effect of single-donor platelets on AR gene
targets. Using individual platelets from healthy donors (“D,” “E,” “F”)
and prostate cancer patients (#3, #4, #5, and #6; Table 1), we evaluated
platelet effect on PSA and TMPRSS2 expression in LNCaP-AR cells.
We selected at random patients whose platelets contained detectable
levels of T and found that platelets from two of three healthy donors and
three of four CRPC patients contained sufficient levels of androgens to
significantly induce activation of PSA and/or TMPRSS2 (Figure 3B,
left and right panels) in AR-dependent cells.
Discussion
Platelets have been demonstrated to modulate tumor growth through
direct delivery of their content to cancer cells [11,12]. Nevertheless, to
date, the precise role of platelets in prostate cancer progression remainsunclear; and furthermore, an examination of platelet-derived androgens
in prostate cancer biology has not been described. Previous reports
profiling intraplatelet mRNA content demonstrated the expression of
steroidogenic dehydrogenases involved in the production of androgens
[18].Moreover, prior findings that platelets are capable of producing the
androgen dehydroepiandrosterone [13] and that platelets from healthy
men possess detectable levels of androgens [19] led us to further assay the
intraplatelet T biosynthetic pathway in the context of prostate cancer.
The data presented in this report demonstrate (a) that the full intact
T biosynthetic pathway is present within platelets of healthy men and
men with CRPC; (b) de novo T synthesis from cholesterol within
platelets frommen with CRPC exhibiting clinical abiraterone resistance,
despite ADT; and (c) that platelets from men with prostate cancer
contain a pool of T sufficient to induce AR signaling in prostate cancer
cells (Supplementary Figure S3). These findings constitute a novel
mechanism through which platelets may promote and sustain the
growth of lethal prostate cancer.
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Figure 3. Platelet-derived T regulates AR target genes in LNCAP-AR cells. (A) Relative mRNA expression levels of PSA (left panel) and
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“PB treated”; cells treated with platelets from individual healthy donors “D”, “E,” and “F” resuspended in platelet buffer: “+ healthy
donors’ platelets in PB”; and cells treated with platelets from individual prostate cancer patients #3, #4, #5, and #6 (from Table 1)
resuspended in platelet buffer: “+ Prostate cancer patients’ platelets in PB” (significance: *P b .05, ***P b .001).
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ADT for advanced prostate were able to metabolize T from its
precursor cholesterol. Furthermore, platelets from all healthy men
(n = 10) and from men with prostate cancer (n = 18) men, including
10 men with CRPC and currently undergoing ADT, contained
detectable levels of T. These data suggest that platelets possess T
biosynthetic activity that is reflective of the disease state. That is to
say, a known mechanism of castrate resistance involves prostate cancer
cell de novo androgen biosynthesis. Here we show that platelets also
possess this ability and hence may serve as a new platform to assay,
study, and target extragonadal steroid biosynthesis in advanced
prostate cancer. Further study of how platelets are capable of
producing T in the setting of CRPC, inclusive of abiraterone
resistance, may shed important light on similar processes at work in
the tumor itself.
We examined the ability of the new-generation CYP17A1-block-
ing drug abiraterone (commonly used in ADT in CRPC patients) to
inhibit T biosynthesis in platelets and found that abiraterone was able
to inhibit platelet capacity to generate T from cholesterol but only inplatelets from men with clinical sensitivity to the drug. Development
of abiraterone resistance is a growing and common clinical problem,
with many men manifesting signs and symptoms of disease
progression within 6 to 12 months following abiraterone treatment
initiation [7]. Hence, although further studies are needed, our
preliminary findings that platelets from men with abiraterone
resistance are capable of T generation from cholesterol suggest that
platelet analysis of men with CRPC may potentially provide evidence
of impending abiraterone failure and guide therapeutic decision
making. IN addition, our data also indicate that molecular alterations
that support CRPC may not be exclusive to the tumor but may also
be present in other tissues (e.g., platelets), suggesting a more systemic
CRPC potentiating phenotype than has been previously reported.
Intriguingly, we observed that platelets of five out of seven men
with high-risk prostate cancer contained significantly higher levels of
T compared to healthy controls (data not shown). Additional studies
are needed to corroborate this observed association of relatively high
intraplatelet T levels and aggressive disease. Still, in this setting
where prostate cancer is androgen dependent, one might speculate
496 Platelet-Synthesized Testosterone in Men with PC Zaslavsky et al. Neoplasia Vol. 17, No. 6, 2015that intratumoral delivery of high amounts of T by platelets could
promote cancer growth.
Taken together, our findings provide evidence for a functional role
for platelets in promoting CRPC through the paracrine production of
androgens. Moreover, our work identifies platelets as a potentially
important site of extragonadal androgen biosynthesis as well as a
possible novel therapeutic target in advanced prostate cancer. Further
work is needed to define the upstream causes and downstream effects
of platelet-derived androgen production and delivery to tumor cells in
prostate cancer.
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